Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31569967 | 0.90 | TSHR (0.36) | TSHR | |
| SCHEMBL20869261 | 0.87 | TSHR (0.42) | LMNATSHRALDH1A1HPGD | |
| SCHEMBL17459562 | 0.85 | LMNA (0.32) | LMNAL3MBTL1MAPK1ALDH1A1HPGD | |
| SCHEMBL19339207 | 0.85 | LMNA (0.32) | LMNAL3MBTL1MAPK1ALDH1A1HPGD | |
| SCHEMBL17468591 | 0.85 | LMNA (0.32) | LMNAL3MBTL1MAPK1ALDH1A1HPGD | |
| SCHEMBL12222390 | 0.85 | LMNA (0.32) | LMNAL3MBTL1MAPK1ALDH1A1HPGD | |
| SCHEMBL1338928 | 0.84 | KDM4E (0.31) | LMNAL3MBTL1KDM4ETP53POLB | |
| SCHEMBL20859051 | 0.82 | TSHR (0.48) | LMNAL3MBTL1KDM4ETP53POLB | |
| SCHEMBL22995757 | 0.80 | TSHR (0.46) | LMNATSHRALDH1A1HPGD | |
| SCHEMBL19309616 | 0.80 | TSHR (0.46) | TSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230136-A1 | METHOD FOR PRODUCING KETONES | BAYER AKTIENGESELLSCHAFT (DE) | 2025-07-17 | — | — | US | claimed |
| CN-118891253-A | Process for preparing ketones | 拜耳公司 | 2024-11-01 | — | — | CN | claimed |
| WO-2023180162-A1 | METHOD FOR PRODUCING KETONES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-28 | — | — | WO | claimed |
| EP-4355748-B1 | SUBSTITUTED PYRROLO[2,3-D]PYRIMIDINES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION | SANOFI SA (FR) | 2026-05-13 | — | — | EP | disclosed |
| EP-4212523-B1 | PYRAZOLE AMIDE COMPOUNDS AS IRAK INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-3870583-B1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727940-A1 | DIHYDROPYRIMIDINE-2, 4 (1H, 3H) -DIONE-CONTAINING POLYCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREOF AND USE THEREOF | Linkcure Therapeutics (KY) | 2026-04-22 | — | — | EP | disclosed |
| US-12606568-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | UNIV MICHIGAN (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-0719259-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES, PROCESS FOR PRODUCING THEM AND THEIR USE AS PESTICIDES AND FUNGICIDES | Hoechst Schering AgrEvo GmbH (DE) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995031441-A1 | HETEROCYCLYLAMINO- AND HETEROCYCLYLOXY-CYCLOALKYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PESTICIDES AND FUNGICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 1995-11-23 | — | — | WO | disclosed |
| WO-1995007894-A1 | SUBSTITUTED PYRIDINES AND PYRIMIDINES, PROCESS FOR PRODUCING THEM AND THEIR USE AS PESTICIDES AND FUNGICIDES | HOECHST SCHERING AGREVO GMBH (DE) | 1995-03-23 | — | — | WO | disclosed |
| EP-0317332-B1 | SULFONANILIDE COMPOUNDS | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1993-05-19 | — | — | EP | disclosed |
| US-4885367-A | ANTIINFLAMMATORY AGENTS, ANTIPYRETICS, ANALGESICS; SIDE EFFECT REDUCTION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1989-12-05 | — | — | US | disclosed |
| EP-0317332-A2 | Sulfonanilide compounds | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1989-05-24 | — | — | EP | disclosed |
| US-4466977-A | N-[2-Amino(oxy- or thia- group-substituted-cycloaliphatic)]benzeneacetamides and -benzamide analgesics | THE UPJOHN COMPANY (US) | 1984-08-21 | — | — | US | disclosed |
| EP-0108602-A1 | N-(2-aminocycloalkyl)benzamide and benzeneacetamide derivatives | THE UPJOHN COMPANY (US) | 1984-05-16 | — | — | EP | disclosed |
| US-4360531-A | Substituted cycloalkanes | THE UPJOHN COMPANY (US) | 1982-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595253-B2 | Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof | JAK1, JAK3, JAK2 | LMNA 3046/4885L3MBTL1 3609/4885KDM4E 2018/4885 |
| US-12606568-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCD1, SMARCC1 | LMNA 793/4885L3MBTL1 2778/4885KDM4E 518/4885 |
| US-20250230136-A1 | METHOD FOR PRODUCING KETONES | PC, BCKDK, HOGA1 | LMNA 1381/4885L3MBTL1 4672/4885KDM4E 1411/4885 |
| US-20260092071-A1 | COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF | SMARCC2, SMARCC1, SMARCA2 | LMNA 582/4885L3MBTL1 3719/4885KDM4E 1118/4885 |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BCL6B | LMNA 1171/4885L3MBTL1 3498/4885KDM4E 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.